Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

GSK, other drugmakers bet on post-Brexit UK science

share with twitter share with LinkedIn share with facebook
share via e-mail
12/06/2017 | 01:21pm CEST
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

LONDON (Reuters) - Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit.

The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union.

Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.

But the highly regulated sector faces potential obstacles to trade as a result of Brexit unless London and Brussels manage to align regulatory regimes for medicines.

In a bid to soften the blow, the government has backed a report by immunologist and geneticist John Bell designed to boost the pharmaceutical sector via fresh public-private collaborations.

That has paved the way for the Life Sciences Sector Deal, which will see GSK invest 40 million pounds of new money in genomic research, including a plan to sequence DNA from all 500,000 volunteer participants enrolled in UK Biobank, the world's most detailed biomedical database.

GSK's head of research Patrick Vallance said the deal showed Britain remained an attractive place for drug discovery, but he cautioned: "The UK needs to recognise going forward that science is an international endeavour, not a parochial endeavour."

Other investments by pharma companies include plans by Johnson & Johnson and the Medicines Co to work on new clinical trials and genetic research by AstraZeneca.

U.S. drugmaker Merck & Co had already announced plans to expand UK research operations under the deal last week.

In all, the government said the deal brought together existing and future commitments by 25 global organisations.

Other companies in discussions with the government about investments include Philips, Roche Diagnostics, Siemens, GE Healthcare and Toshiba Medical Systems.

As a key part of the deal, the government said it was committed to increasing investment in R&D to 2.4 percent of GDP by 2027 and 3 percent over the longer term.

(Reporting by Ben Hirschler; Editing by Gareth Jones and Louise Heavens)

By Ben Hirschler

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE -0.21% 1552.8 Delayed Quote.17.66%
JOHNSON & JOHNSON -1.05% 121.32 Delayed Quote.-12.25%
MERCK AND COMPANY -1.68% 60.99 Delayed Quote.10.24%
THE MEDICINES COMPANY -0.24% 36.81 Delayed Quote.34.97%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
06/18FASTER MEDICINE : £56 million innovation centre for Scotland
06/16ASTRAZENECA : £56m medicine base is set for Inchinnan
06/152.5B U.K. fund, Alzheimer`s failure, Alexion-Complement, Targovax tumbles and..
06/14ASTRAZENECA : Data from AstraZeneca Advance Knowledge in Drug Development [A Pra..
06/14ASTRAZENECA : Findings from AstraZeneca Reveals New Findings on Tumor Necrosis F..
06/14ASTRAZENECA : Researchers from AstraZeneca Report Recent Findings in Multiple Sy..
06/14CAH Closer To FDA Approval, Another Alzheimer`s Disease Drug Fails, VTVT Tank..
06/12Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer's Drug Trials -- Update
06/12ASTRAZENECA : Update on Phase III clinical trials of lanabecestat for Alzheimer'..
06/12ASTRAZENECA : EU gives nod to expanded label for AZs Tagrisso
More news
News from SeekingAlpha
06/15Avoiding The 'Black Hole' Of Disease Development 
06/153 THINGS IN BIOTECH, JUNE 14 : Another Big Win In A Rare Area For Merck 
06/14YOUR DAILY PHARMA SCOOP : Sage On Accelerated Path, GenSight Positive Data, Astr.. 
06/13An Alzheimer's Statement 
06/12Xeris Pharmaceuticals To Raise $75 Million In IPO 
Financials ($)
Sales 2018 22 365 M
EBIT 2018 5 337 M
Net income 2018 1 982 M
Debt 2018 14 731 M
Yield 2018 3,83%
P/E ratio 2018 37,83
P/E ratio 2019 30,58
EV / Sales 2018 4,71x
EV / Sales 2019 4,44x
Capitalization 90 670 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 74,4 $
Spread / Average Target 3,8%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA5.41%90 670
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
MERCK AND COMPANY10.24%166 880